EULAR 2026: Polymyalgia Rheumatica Guidelines Incorporate RWE

Polymyalgia rheumatica (PMR) is a chronic inflammatory condition primarily affecting individuals over 50 years of age, characterized by bilateral shoulder and hip girdle pain and stiffness. The cornerstone of treatment remains glucocorticoids, which are highly effective in symptom resolution but carry a significant burden of dose- and duration-dependent adverse effects, including osteoporosis, diabetes, and cardiovascular complications.¹ The clinical dilemma lies in achieving rapid symptom control while minimizing long-term glucocorticoid exposure. Current diagnostic criteria, such as the EULAR/ACR 2012 classification criteria, emphasize clinical presentation alongside inflammatory markers like erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP).² However, these criteria do not fully account for the heterogeneity observed in real-world patient populations, particularly regarding response to therapy and risk of relapse.

Practical Implications of Evolving Guidelines

The EULAR 2026 guidelines for polymyalgia rheumatica represent an evolution in management by formally integrating real-world evidence (RWE) into their recommendations. This shift acknowledges that data derived from routine clinical practice, including large patient registries and electronic health records, can provide valuable insights into treatment effectiveness, safety profiles, and patient outcomes that may not be fully captured in highly controlled randomized controlled trials (RCTs).³ For PMR, RWE has been particularly instrumental in refining glucocorticoid tapering strategies and identifying patient subgroups at higher risk of relapse or glucocorticoid-related adverse events. For instance, RWE has informed more nuanced approaches to initial glucocorticoid dosing, moving away from a 'one-size-fits-all' model towards recommendations that consider individual patient characteristics, such as age, comorbidities, and baseline inflammatory markers.⁴

Specifically, the updated guidelines are expected to provide more granular recommendations on the initial prednisone equivalent dose, with a likely emphasis on starting doses between 12.5 mg and 25 mg daily, depending on disease severity and patient factors.⁵ Furthermore, the guidelines are anticipated to offer clearer guidance on the rate of glucocorticoid tapering, suggesting slower reduction schedules for patients with a history of rapid relapse or those with persistent inflammatory markers.⁶ The integration of RWE has also highlighted the utility of steroid-sparing agents, such as methotrexate, in specific patient populations. While methotrexate's role in PMR has been debated, RWE has provided further context regarding its efficacy in reducing cumulative glucocorticoid dose and preventing relapse in patients requiring prolonged glucocorticoid therapy or those intolerant to higher doses.⁷ The guidelines are expected to recommend considering methotrexate earlier in patients with risk factors for glucocorticoid toxicity or those who fail to achieve remission on standard glucocorticoid regimens.⁸

The EULAR 2026 guidelines are also expected to emphasize the importance of shared decision-making, incorporating patient preferences and values into treatment plans. RWE has demonstrated variability in patient experiences and priorities, underscoring the need for individualized care.⁹ This includes discussions about the risks and benefits of glucocorticoids, the potential role of steroid-sparing agents, and the importance of lifestyle modifications. The guidelines will likely reinforce the need for regular monitoring of glucocorticoid-related adverse events, such as bone mineral density assessments and glucose monitoring, given the long-term nature of PMR treatment.¹⁰

While RWE offers valuable complementary data, it is not without limitations. Observational studies, which form a significant part of RWE, are susceptible to confounding by indication and selection bias.¹¹ The absence of randomization means that direct causal inferences can be more challenging to establish compared to RCTs. Therefore, the EULAR 2026 guidelines will likely present RWE as a tool to inform and refine existing recommendations, rather than to replace evidence from high-quality RCTs entirely. Future research will need to focus on developing robust methodologies for integrating RWE with RCT data to provide the most comprehensive and actionable guidance for clinicians. Further studies are also needed to validate specific RWE-derived treatment algorithms in prospective cohorts.¹²